Biogen Inc
XETRA:IDP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Biogen Inc (IDP) under the Base Case is EUR per share.
Compared with the current market price of 165.68 EUR, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Biogen Does
Biogen is a biotechnology company that develops and sells medicines for serious diseases, with a long focus on conditions that affect the brain and nervous system. Its main products are prescription drugs for diseases such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, and certain rare neurological disorders. It also works on therapies for immunology and related areas, but its business is centered on specialty medicines that are prescribed by doctors rather than sold over the counter.
- Headquarters
- United States of America US
- Employees
- 7 500
- IPO date
- Sep 17, 1991
Biogen has a narrow economic moat
Patents and legal protection against competing copies prevent rivals from freely copying several of Biogen’s medicines, helping protect their sales and profits. That protection applies to individual drugs rather than the whole company, while competing treatments already give patients alternatives in important markets.
Read the full moat analysis
Revenue & Expenses Breakdown
Biogen Inc
Earnings Waterfall
Biogen Inc
Continue IDP Research
Decided on Biogen? Get an email when IDP reaches the price you’d buy at. Free with an account.
Other Biogen listings
What is the Intrinsic Value of one IDP stock?
The intrinsic value for
Biogen Inc (IDP) under the Base Case is EUR.
Is IDP stock undervalued or overvalued?
Compared with the current market price of 165.68 EUR, the stock appears .